Preferred Label : Anti-B7-H3 Antibody-drug Conjugate HS-20093;
NCIt synonyms : Anti-B7-H3 ADC HS-20093; Anti-B7H3 ADC HS-20093;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal
antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276)
covalently linked to a topoisomerase inhibitor (TOPOi), with potential antineoplastic
activity. Upon administration of anti-B7-H3 ADC HS-20093, the anti-B7-H3 monoclonal
antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding
and internalization, the TOPOi is released, and inhibits DNA topoisomerase activity,
thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell
apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3,
a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily,
is an immunoregulatory protein overexpressed on certain tumor cell types and on various
immune cells. It is a negative regulator of the T-cell activation and its overexpression
plays a key role in tumor cell invasion and metastasis.;
Molecule name : HS 20093; HS-20093; GSK-5764227; GSK 5764227;
NCI Metathesaurus CUI : CL1792009;
Origin ID : C187121;
UMLS CUI : C5706368;
Semantic type(s)
- concept_is_in_subset
- has_target
